Eli Lilly and Company (NYSE:LLY) Shares Acquired by Advisory Services Network LLC

Advisory Services Network LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 6.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 43,303 shares of the company’s stock after purchasing an additional 2,641 shares during the quarter. Eli Lilly and Company makes up 0.6% of Advisory Services Network LLC’s portfolio, making the stock its 16th biggest holding. Advisory Services Network LLC’s holdings in Eli Lilly and Company were worth $25,242,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Lipe & Dalton acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Tidemark LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $29,000. Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company in the third quarter worth about $36,000. St. Johns Investment Management Company LLC boosted its holdings in Eli Lilly and Company by 123.3% in the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after purchasing an additional 37 shares during the last quarter. Finally, O Brien Wealth Partners LLC grew its stake in Eli Lilly and Company by 70.5% during the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 31 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.1 %

Shares of LLY stock traded down $1.02 during trading on Friday, reaching $807.43. The company’s stock had a trading volume of 1,758,200 shares, compared to its average volume of 2,993,883. The company has a market cap of $767.39 billion, a price-to-earnings ratio of 119.20, a price-to-earnings-growth ratio of 1.75 and a beta of 0.37. Eli Lilly and Company has a one year low of $419.80 and a one year high of $820.60. The business has a fifty day moving average price of $764.43 and a 200-day moving average price of $690.85. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.62 EPS. Analysts anticipate that Eli Lilly and Company will post 13.78 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. Eli Lilly and Company’s payout ratio is 76.58%.

Analysts Set New Price Targets

LLY has been the subject of a number of research analyst reports. Citigroup lifted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. BMO Capital Markets upped their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Argus lifted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. The Goldman Sachs Group upped their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Finally, Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $769.53.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.